FDA approves Stanford Medicine-developed drug that treats rare …
6 天之前 · People who are diagnosed with ATTR-CM experience a buildup of a misfolded protein called transthyretin in their hearts, causing stiffness that prevents the heart from beating …
FDA approves drug for heart disorder caused by transthyretin …
2024年11月25日 · The U.S. Food and Drug Administration has approved Attruby (acoramidis) to treat adults with cardiomyopathy (disorder that affects heart muscle) of wild-type or variant …
FDA Approves Attruby - Drugs.com
About Attruby™ (acoramidis) Attruby is the only near-complete (≥90%) stabilizer of Transthyretin (TTR) approved in the U.S. for the treatment of adult patients with ATTR-CM to reduce …
FDA Approves BridgeBio Pharma's Drug For Rare Heart Disease, …
2024年11月25日 · On Friday, the FDA approved BridgeBio Pharma, Inc.’s (NASDAQ: BBIO) Attruby (acoramidis), an orally-administered near-complete (≥90%) stabilizer of Transthyretin …
FDA approves BridgeBio’s Attruby for ATTR-CM treatment
2024年11月25日 · The US Food and Drug Administration (FDA) has approved BridgeBio Pharma’s Attruby (acoramidis), an oral transthyretin (TTR) stabiliser, to treat adults with …
FDA Approves Acoramidis (Attruby) for ATTR-CM
2024年11月23日 · The US Food and Drug Administration has approved acoramidis (Attruby) for the treatment of adults with transthyretin amyloid cardiomyopathy (ATTR-CM) to reduce …
FDA Approves First ‘Near-Complete’ Stabilizer to Treat ATTR ...
2024年11月25日 · Acoramidis (Attruby; BridgeBio), a drug that stabilizes transthyretin and has demonstrated benefit on cardiovascular outcomes, has been approved by the US Food and …
BridgeBio heart disease drug Attruby wins FDA approval | STAT
2024年11月23日 · The Food and Drug Administration approved on Friday a new medicine from BridgeBio for patients with a progressive heart disease — the first new treatment for the …
Attruby™ (acoramidis), a Near Complete TTR Stabilizer (≥90%), …
2024年11月23日 · -Attruby is the first and only approved product with a label specifying near-complete stabilization of TTR. Attruby has been shown to preserve the native function of TTR …
US FDA approves BridgeBio's drug for rare heart condition (Nov 22)
2024年11月23日 · The oral drug, branded as Attruby, was approved to treat adult patients with transthyretin amyloid cardiomyopathy (ATTR-CM), in which faulty transthyretin proteins …